BioLASCO Taiwan Co. Ltd. AI Stock Analysis
BioLASCO Taiwan Co. Ltd. (6662) AI Stock Analysis
BioLASCO Taiwan Co. Ltd.
(TPEx:6662)
BioLASCO earns a moderate score. Its greatest strengths are a conservatively financed balance sheet (debt-to-equity of 0.20, equity funding ~77% of assets), consistent profitability with mid-teens net margins, and a high 5.46% dividend yield at a reasonable 17.75x earnings. These are offset by the main risk: stalled growth. Revenue declined in the latest year, gross and operating margins have compressed for several years, return on equity has fallen to single digits, and free cash flow has been erratic due to uneven capital spending. Technically, the stock is trading flat against all key moving averages with neutral RSI and slightly soft MACD momentum, offering no directional catalyst. Overall, this is a stable, income-oriented small-cap whose key challenge is reigniting revenue growth and restoring margin momentum.
BioLASCO Taiwan Co. Ltd. (6662) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 727.38M
- Dividend Yield
- 5.46%
- Average Volume (3M)
- 4,415
- Price to Earnings (P/E)
- 17.8
- Beta (1Y)
- -0.03
- Revenue Growth
- -8.71%
- EPS Growth
- -16.08%
- Country
- TW
- Employees
- 91
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
BioLASCO Taiwan Co. Ltd. Business Overview & Revenue Model
Company Description
BioLASCO Taiwan Co., Ltd., established in Taipei in 1990, operates as an international supplier of bio-materials and surgical support services. The company specializes in breeding and producing Specific Pathogen-Free (SPF) laboratory rodents, encompa...
BioLASCO Taiwan Co. Ltd. Financial Statement Overview
Summary
A financially sound but low-growth profile. The balance sheet is the standout (score 78): debt-to-equity of just 0.20, equity funding ~77% of assets, and capital spending funded internally. The income statement is weaker (score 60): revenue fell to NT$262.7m from NT$292.5m, reversing two years of double-digit growth, while gross margin has eroded from 46.2% in 2021 to 38.7% and operating margin has compressed since 2020. Cash flow is reliable but lumpy (score 65): operating cash flow of NT$48.7m exceeds net income of NT$42.4m, confirming good earnings quality, but it has declined year over year and free cash flow of NT$27.1m converts only ~56% of net income. Return on equity has slipped to 9.3% from 13.4% in 2020, indicating the large equity base is not being deployed into high-return growth.
Income Statement
60NeutralBalance Sheet
78PositiveCash Flow
65Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 258.04M | 262.66M | 292.50M | 264.72M | 235.91M | 227.58M |
| Gross Profit | 100.51M | 101.62M | 114.76M | 104.35M | 104.49M | 105.11M |
| EBITDA | 57.67M | 59.58M | 67.64M | 73.86M | 59.50M | 67.34M |
| Net Income | 40.89M | 42.43M | 44.03M | 49.74M | 42.31M | 45.15M |
Balance Sheet | ||||||
| Total Assets | 597.69M | 592.58M | 612.67M | 573.14M | 569.69M | 574.26M |
| Cash, Cash Equivalents and Short-Term Investments | 141.27M | 136.41M | 162.52M | 201.67M | 227.20M | 244.47M |
| Total Debt | 87.01M | 93.58M | 107.01M | 58.21M | 65.94M | 69.18M |
| Total Liabilities | 170.24M | 134.86M | 163.29M | 111.98M | 115.05M | 113.91M |
| Stockholders Equity | 427.45M | 457.72M | 449.38M | 461.16M | 454.64M | 460.36M |
Cash Flow | ||||||
| Free Cash Flow | 33.73M | 27.06M | 931.00K | 27.83M | 40.42M | 66.49M |
| Operating Cash Flow | 43.89M | 48.71M | 56.86M | 29.46M | 44.69M | 70.84M |
| Investing Cash Flow | -8.14M | -20.32M | -97.60M | -8.83M | -28.72M | -13.17M |
| Financing Cash Flow | -55.79M | -54.50M | 4.59M | -46.16M | -48.63M | -57.97M |
BioLASCO Taiwan Co. Ltd. Peers Comparison
Overall Rating
- TW:666264Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6662 | 64Neutral | TWD 727.39M | 17.75 | ― | 5.46% | -8.71% | -16.08% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6662 | BioLASCO Taiwan Co. Ltd. | 28.40 | -1.20 | -4.05% | |
| TW:4732 | Naturewise Biotech & Medicals Corporation | 15.20 | -5.30 | -25.85% | |
| TW:6572 | PlexBio Co., Ltd. | 6.28 | -2.72 | -30.22% | |
| TW:6817 | Winston Medical Supply Co., Ltd. | 37.50 | -60.57 | -61.76% | |
| TW:6939 | TFBS Bioscience, Inc. | 18.90 | -4.85 | -20.42% | |
| TW:7790 | Spirit Scientific Co., Ltd. | 39.65 | -33.32 | -45.66% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026